Compare American States Water Company (AWR) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Quest Diagnostics Inc — how do they compare? American States Water Company trades at $87.85 (market cap $3.47B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 7.6× American States Water Company's market cap, and American States Water Company pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| AWR | DGX | |
|---|---|---|
Market Cap | $3.47B | $26.21B |
Sector | Utilities | Health |
52-Week High | $89.28 | $238.50 |
52-Week Low | $70.10 | $173.49 |
Enterprise Value | $4.37B | $31.97B |
Dividend Yield | 2.49% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.
Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
